A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.